Zurich, Switzerland

Torsten Woehr

This inventor holds 1 USPTO granted patent. Top assignee: Debiopharm S.a.. Active years: 2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Torsten Woehr. Retrieved from https://idiyas.com/inventor/torsten-woehr-9e24ycrf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Torsten Woehr: Innovator in Cyclosporin Derivatives

Introduction

Torsten Woehr is a notable inventor based in Zurich, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cyclosporin derivatives. His innovative work has led to advancements in medical treatments and drug production.

Latest Patents

Woehr holds a patent for "Cyclosporin derivatives and method for the production of said derivatives." This invention relates to cyclosporin derivatives, where the peptide chain includes at least one pseudo-proline type non-natural amino acid radical. The patent also encompasses a method for producing these derivatives, showcasing Woehr's expertise in biochemistry and pharmaceutical sciences.

Career Highlights

Torsten Woehr is currently associated with Debiopharm S.A., a company known for its commitment to developing innovative therapies. His work at Debiopharm has allowed him to focus on creating effective pharmaceutical solutions that address critical health issues.

Collaborations

Woehr has collaborated with esteemed colleagues such as Roland M Wenger and Manfred Mutter. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical products.

Conclusion

Torsten Woehr's contributions to the field of cyclosporin derivatives exemplify his dedication to innovation in pharmaceuticals. His work continues to impact the industry positively, paving the way for future advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…